ABVC BioPharma Inc. (ABVC) Financial Statements (2025 and earlier)

Company Profile

Business Address 44370 OLD WARM SPRINGS BLVD.
FREMONT, CA 94538
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3131391615,9374,273144
Cash and cash equivalent24860855,8294,273144
Short-term investments657976108  
Restricted cash and investments615 1,306737  
Receivables 2856283696334
Inventory, net of allowances, customer advances and progress billings   26  
Inventory   26  
Prepaid expense     17277
Other undisclosed current assets1,2511,5166642,6431,031323
Total current assets:2,1801,6572,9879,6256,173878
Noncurrent Assets
Operating lease, right-of-use asset6408091,1611,4721,773524
Property, plant and equipment5117,969574526515521
Long-term investments and receivables2,2592,5281,9839331,1913,365
Due from related parties1,141   
Long-term investments2,2592,5288429331,1913,365
Prepaid expense  79135119119135
Deferred income tax assets   1179821,791 
Other noncurrent assets133     
Other receivable, after allowance for credit loss 3,941114
Other undisclosed noncurrent assets(2,125)1,3372,89741461,504
Total noncurrent assets:5,36012,8366,8684,0735,4346,050
TOTAL ASSETS:7,54014,4939,85513,69811,6076,928
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6843,6962,9101,30123685
Employee-related liabilities  661
Accounts payable     2324
Accrued liabilities6843,6962,9101,301  
Deferred revenue8180    
Debt8401,4691,8941,6401,7362,336
Other liabilities 173    
Due to related parties636393288426
Other undisclosed current liabilities4,9525153803582,7973,367
Total current liabilities:6,5575,9325,8203,6924,8446,814
Noncurrent Liabilities
Long-term debt and lease obligation    1,1253,957236
Long-term debt, excluding current maturities     2,500 
Liabilities, other than long-term debt237407792   
Operating lease, liability2374077921,1251,457236
Other undisclosed noncurrent liabilities22228(1,114)(1,313)3
Total noncurrent liabilities:2584298001,1354,100238
Total liabilities:6,8166,3626,6194,8288,9457,053
Equity
Equity, attributable to parent, including:1,2268,3883,0998,8443,438(151)
Common stock14833292419
Treasury stock, value(8,910)(8,902)(9,100)(9,100)(9,100)(9,100)
Additional paid in capital78,59582,63767,90758,11440,75228,180
Accumulated other comprehensive income446516517540  
Accumulated deficit(68,950)(65,420)(54,904)(38,481)(25,642)(15,851)
Stockholders' equity note, subscriptions receivable  (451)(1,354)(2,257)(3,160)(4,063)
Other undisclosed equity, attributable to parent31   565664
Equity, attributable to noncontrolling interest(502)(257)13827(776)26
Total equity:7248,1313,2368,8702,662(125)
TOTAL LIABILITIES AND EQUITY:7,54014,4939,85513,69811,6076,928

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues510152970356483702
Loss on disposition of assets for financial service operations  (222) (270)(1,169)(210)
Cost of revenue(1)(302)(286)(5)(19)(20)
Provision for loan, lease, and other losses      
Gross profit:509(150)683351464682
Operating expenses(5,214)(8,067)(15,798)(12,057)(8,970)(4,140)
Other undisclosed operating loss      
Operating loss:(4,705)(8,217)(15,114)(11,706)(8,506)(3,459)
Nonoperating income (expense)(664)(2,438)(400)495(2,308)(552)
Investment income, nonoperating(252)185 1355143
Gain (loss), foreign currency transaction, before tax(25)23 426(3)0
Other nonoperating income (expense)1343(400)2217593
Interest and debt expense(826)(20)(294)(227)(405)(1)
Loss from continuing operations before equity method investments, income taxes:(6,195)(10,674)(15,809)(11,438)(11,219)(4,011)
Other undisclosed income from continuing operations before income taxes826202942274051
Loss from continuing operations before income taxes:(5,370)(10,654)(15,515)(11,211)(10,814)(4,010)
Income tax expense (benefit)111(256)(798)(825)22077
Loss from continuing operations:(5,259)(10,910)(16,312)(12,036)(10,594)(3,933)
Loss before gain (loss) on sale of properties:(12,036)(10,594)(3,933)
Net loss:(5,259)(10,910)(16,312)(12,036)(10,594)(3,933)
Net income (loss) attributable to noncontrolling interest356395(111)12,036  
Other undisclosed net loss attributable to parent    (12,036)  
Net loss attributable to parent:(4,903)(10,516)(16,423)(12,036)(10,594)(3,933)
Other undisclosed net income (loss) available to common stockholders, basic10,162  (803)  
Net income (loss) available to common stockholders, diluted:5,259(10,516)(16,423)(12,839)(10,594)(3,933)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(5,259)(10,910)(16,312)(12,036)(10,594)(3,933)
Comprehensive loss:(5,259)(10,910)(16,312)(12,036)(10,594)(3,933)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest356395(111)12,036  
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(71)(1)(23)(12,864)704299
Comprehensive loss, net of tax, attributable to parent:(4,974)(10,516)(16,446)(12,864)(9,890)(3,634)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: